title: Varicella disease after introduction of varicella vaccine in the United States, 1995-2000.
abstract: BACKGROUND
  Before licensure of varicella vaccine in 1995, varicella was a universal childhood disease in the United States, causing 4 million cases, 11,000 hospitalizations, and 100 deaths every year.
  
  
  OBJECTIVE
  To examine population-based disease surveillance data in 3 communities to document the impact of the varicella vaccination program.
  
  
  METHODS
  Active surveillance for varicella conducted among the populations of Antelope Valley, Calif; Travis County, Tex; and West Philadelphia, Pa; from January 1, 1995, to December 31, 2000. Reporting sites included child care centers, schools, universities, physicians, public health clinics, hospitals, emergency departments, and households.
  
  
  METHODS
  Trends in number and rate of varicella cases and hospitalizations; varicella vaccine coverage.
  
  
  RESULTS
  From 1995 through 1998, in each surveillance area, the number of verified varicella cases varied from year to year with marked springtime seasonality. In 1999, the number and rates of varicella cases and hospitalizations declined markedly. From 1995 through 2000, in Antelope Valley, Travis County, and West Philadelphia, varicella cases declined 71%, 84%, and 79%, respectively. Cases declined to the greatest extent among children aged 1 to 4 years, but cases declined in all age groups, including infants and adults. In the combined 3 surveillance areas, hospitalizations due to varicella declined from a range of 2.7 to 4.2 per 100,000 population in 1995 through 1998 to 0.6 and 1.5 per 100,000 population in 1999 and 2000, respectively (P =.15). By 2000, vaccine coverage among children aged 19 to 35 months was 82.1%, 73.6%, and 83.8% in Los Angeles County, Texas, and Philadelphia County, respectively.
  
  
  CONCLUSIONS
  Varicella disease has declined dramatically in surveillance areas with moderate vaccine coverage. Continued implementation of existing vaccine policies should lead to further reductions of varicella disease in these communities and throughout the United States.
authors.affiliation: Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, Mailstop E-62, Atlanta, GA 30333, USA. jseward@cdc.gov
authors.forename: Jane F
authors.initials: JF
authors.lastname: Seward
authors.forename: Barbara M
authors.initials: BM
authors.lastname: Watson
authors.forename: Carol L
authors.initials: CL
authors.lastname: Peterson
authors.forename: Laurene
authors.initials: L
authors.lastname: Mascola
authors.forename: Jan W
authors.initials: JW
authors.lastname: Pelosi
authors.forename: John X
authors.initials: JX
authors.lastname: Zhang
authors.forename: Teresa J
authors.initials: TJ
authors.lastname: Maupin
authors.forename: Gary S
authors.initials: GS
authors.lastname: Goldman
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Tabony
authors.forename: Kimberly G
authors.initials: KG
authors.lastname: Brodovicz
authors.forename: Aisha O
authors.initials: AO
authors.lastname: Jumaan
authors.forename: Melinda
authors.initials: M
authors.lastname: Wharton
mesh_terms: D000293:Adolescent; D000328:Adult; D002644:Chickenpox / Q000453:epidemiology* / Q000517:prevention & control; D019433:Chickenpox Vaccine / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D011159:Population Surveillance; D014481:United States / Q000453:epidemiology; D014611:Vaccination / Q000706:statistics & numerical data*
chemical_list: D019433:Chickenpox Vaccine